SCHEMBL3826324

SCHEMBL3826324

Cc1ccc2cc(-c3ccccc3C)ncc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
NPC1 O15118 4/20 0.49
RAB9A P51151 3/20 0.49
CYP2A6 P11509 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAP4K1 Q92918 1/20 0.44
CYP1A2 P05177 6/20 0.44
CYP2D6 P10635 4/20 0.44
CYP2C19 P33261 4/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP3A4 P08684 3/20 0.44
ALOX15 P16050 3/20 0.44
HSD17B10 Q99714 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
IDO1 P14902 1/20 0.41
METAP2 P50579 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831411 0.93 CASP3 (0.50) L3MBTL1NPC1RAB9ACYP2A6TDP1
SCHEMBL807820 0.86 NPC1 (0.62) L3MBTL1NPC1RAB9ACYP2A6TDP1
SCHEMBL3832328 0.84 L3MBTL1 (0.72) L3MBTL1NPC1RAB9ACYP2A6TDP1
SCHEMBL14479276 0.83 L3MBTL1 (0.47) L3MBTL1NPC1RAB9ACYP2A6MAP4K1
SCHEMBL14102704 0.83 NPC1 (0.72) L3MBTL1NPC1RAB9ACYP2A6CYP1A2
SCHEMBL3831108 0.81 CYP2A6 (0.45) L3MBTL1NPC1RAB9ACYP2A6TDP1
SCHEMBL28963415 0.79 NPC1 (0.66) L3MBTL1NPC1RAB9ACYP2A6TDP1
SCHEMBL3828449 0.78 NPC1 (0.55) NPC1RAB9ACYP2A6CYP1A2CASP3
SCHEMBL3830028 0.78 NPC1 (0.55) NPC1RAB9ACYP2A6CYP1A2CASP3
SCHEMBL3826323 0.78 NPC1 (0.50) L3MBTL1NPC1RAB9ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099765-A2 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS Rexahn Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
WO-2008063548-A2 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS REXAHN PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed